Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Carnot Laboratories
Age
65–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients with a diagnosis of Alzheimer's disease were selected according to the criteria of the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA).
Patients had moderate to severe Alzheimer's disease, based on the following assessments:
Mini-Mental State Examination (MMSE) score ≤ 18 in patients with more than 12 years of education; or Montreal Cognitive Assessment (MoCA) score ≤ 18 in patients with more than 12 years of education.
Katz Index of Activities of Daily Living score ≤ 6 and Lawton Instrumental Activities of Daily Living scale score \< 6 out of 8.
Clinical Dementia Rating (CDR) scale score of 2 or 3.
Patients were considered eligible when memantine was selected as the therapeutic option for Alzheimer's disease, according to the treating physician's clinical judgment.
Only patients who were prescribed memantine for the first time were included.
Patients were included if they attended the clinical visit accompanied by their primary caregiver, and if the caregiver agreed to participate and signed the corresponding informed consent.
The primary caregiver had Spanish as their native language or demonstrated functional proficiency in the language.
You may not be if
Patients with a diagnosis of preclinical Alzheimer's disease were excluded.
Patients with a diagnosis of Alzheimer's disease at a stage other than moderate to severe were excluded, based on any of the following scales:
Mini-Mental State Examination (MMSE) score \> 18; or Montreal Cognitive Assessment (MoCA) score \> 18.
Patients with uncontrolled depression (including major depressive disorder) within the last three months were excluded, according to:
Geriatric Depression Scale (GDS) (Yesavage), short form, score ≥ 10.
Patients with uncontrolled anxiety within the last three months were excluded, according to:
Hamilton Anxiety Rating Scale (HAM-A) score ≥ 8.
Patients with contraindications or any other condition preventing the use of memantine, in accordance with the approved prescribing information for SINOLVIR® or EUTEBROL®, were excluded.
Primary caregivers who refused to participate or who were unable to complete the study due to severe sensory impairment or for any other reason were excluded.
Patients with psychiatric disorders or symptoms of non-Alzheimer's disease origin that were active or decompensated at study entry (e.g., delirium, schizophrenia) were excluded.
Patients with active alcohol use at study entry were excluded.
Patients with unstable or uncontrolled neurological conditions, such as active autoimmune or infectious encephalitis, uncontrolled epilepsy, uncontrolled multiple sclerosis, or uncontrolled amyotrophic lateral sclerosis, were excluded.
Patients with active brain neoplasms at study entry were excluded.
